Shopping Cart
Remove All
Your shopping cart is currently empty
Tanezumab
Catalog No. T78282 Copy Product Info
🥰Excellent
Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.
Tanezumab
Copy Product Info🥰Excellent
Catalog No. T78282
Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.
Tanezumab
Cas No. 880266-57-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $172 | - | In Stock | |
| 5 mg | $433 | - | In Stock | |
| 10 mg | $695 | - | In Stock | |
| 25 mg | $1,060 | - | In Stock | |
| 50 mg | $1,430 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.9% (SDS-PAGE); 95.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF (nerve growth factor). It inhibits the sensitisation and conduction of peripheral pain fibres by blocking the interaction between NGF and the p75 and TrkA receptors, thereby treating various acute and chronic pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain. |
| In vitro | Methods: To evaluate the effect of Tanezumab on cell migration, MiaPaCa-2 and CFPAC-1 cells were treated with 100 ng/mL of the drug and incubated for 48 hours before performing a cell migration assay. Results: Tanezumab significantly inhibited the migration of MiaPaCa-2 and CFPAC-1 cells [3]. |
| In vivo | Methods: To evaluate the in vivo efficacy of Tanezumab, MiaPaCa-2 xenograft mouse models were administered 10 mg/kg subcutaneously once daily for 8 weeks. Results: Tanezumab reduced tumor volume and invasive nerve diameter, and alleviated hindlimb dysfunction [3]. |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | NGF/bNGF |
| Molecular Weight | 145.43 kDa |
| Cas No. | 880266-57-9 |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Keywords
Preview
Related Tags: buy Tanezumab | purchase Tanezumab | Tanezumab cost | order Tanezumab | Tanezumab in vivo | Tanezumab in vitro | Tanezumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.